Gamaleya Research Institute 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


«12345678910111213...3233»
  • ||||||||||  Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford
    Journal:  Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary - The HUN-VE study. (Pubmed Central) -  Mar 16, 2022   
    acute hepatitis arising after COVID-19 appears to be a heterogeneous condition: long-term follow-up will help understanding if in some cases the vaccine triggers autoimmune hepatitis or if it is a novel drug-induced nosological entity. Our observational study demonstrated the high or very high effectiveness of five different vaccines in the prevention SARS-CoV-2 infection and COVID-19-related death.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Journal:  Estimating the cost of COVID-19 vaccine deployment and introduction in Ghana using the CVIC tool. (Pubmed Central) -  Mar 11, 2022   
    Our observational study demonstrated the high or very high effectiveness of five different vaccines in the prevention SARS-CoV-2 infection and COVID-19-related death. These findings provide the estimates to inform resource mobilization efforts by government and other partners.
  • ||||||||||  Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Biomarker, Journal:  Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac). (Pubmed Central) -  Mar 9, 2022   
    30% developed ex vivo IFNγ ELISpot responses (significantly lower than AZD1222), and high frequency of CD107a expressing T cells along with memory B cell responses. Although single dose of Gam-COVID-Vac was highly immunogenic, administration of a second dose is likely to be beneficial.
  • ||||||||||  Sputnik Light / Gamaleya Research Institute
    Journal:  Boosting of the SARS-CoV-2-Specific Immune Response after Vaccination with Single-Dose Sputnik Light Vaccine. (Pubmed Central) -  Mar 8, 2022   
    Additionally, we found a strong correlation between RBD-specific IgG titers and VNA in serum, and according to these data vaccination may be recommended when the RBD-specific IgG titers drop to 142.7 binding Ab units/ml or below. In summary, the results of the study demonstrate that vaccination is beneficial for both COVID-19-naive and recovered individuals, especially since it raises serum VNA against the B.1.617.2 variant, one of the five SARS-CoV-2 variants of concern.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Journal:  Acute disseminated encephalomyelitis following vaccination against SARS-CoV-2: A case report. (Pubmed Central) -  Mar 8, 2022   
    Acute disseminated encephalomyelitis (ADEM) is an inflammatory emyelinating disease of the central nervous system that is usually considered a monophasic disease Post-vaccination ADEM has been associated with several vaccines, however, there is scarce information related to SARS-CoV-2 vaccines. We present the case of a 26- year-old female who suffered from ADEM four weeks after Gam-COVID-Vac administration.
  • ||||||||||  Review, Journal:  Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants. (Pubmed Central) -  Mar 5, 2022   
    Additionally, dendritic cells (LV-SMENP-DC) and artificial antigen-presenting (aAPC) cells modified with lentiviral vector have also been developed to inhibit viral activity. Recombinant vaccines against COVID-19 are continuously being applied, and new clinical trials have been tested by interchangeability studies of viral vaccines developed by classical and next-generation platforms.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Journal:  The Sputnik V Vaccine against COVID-19: A Promising Platform for Mass Vaccination. (Pubmed Central) -  Mar 1, 2022   
    Recombinant vaccines against COVID-19 are continuously being applied, and new clinical trials have been tested by interchangeability studies of viral vaccines developed by classical and next-generation platforms. No abstract available
  • ||||||||||  CoronaVac / Sinovac, Bio Farma Indonesia, Covaxin (BBV152 COVID Vaccine) / Bharat Biotech, Indian Council of Medical Research, Ocugen, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Review, Journal:  Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines. (Pubmed Central) -  Feb 22, 2022   
    Among them are BioNTech and Moderna vaccines (mRNA based); ChAdOx1, Gam-COVID-Vac, Janssen vaccines (vector-based); CoronaVac, COVAXIN (virus inactivated); and EpiVacCorona vaccine (viral peptide)...However, no definitive relationship could be established between vaccination administration and the occurrence of these complications. None of the COVID-19 vaccines approved to date have been found to be effective against all of the SARS-CoV-2 variants.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Journal:  Guillain-Barre Syndrome and COVID-19 Vaccine: A Report of Nine Patients. (Pubmed Central) -  Feb 19, 2022   
    The link between the COVID-19 vaccine and GBS is not well understood. Given the prevalence of GBS over the population, this association may be coincidental; therefore, more studies are needed to investigate a causal relationship.
  • ||||||||||  CoronaVac / Sinovac, Bio Farma Indonesia, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Breakthrough COVID Infections: Prevalence of Critical COVID-19 Disease Among Post-Vaccinated Patients in a Tertiary Hospital in the Philippines (Area J, Hall F (North Building, Exhibition Level), Moscone Center) -  Feb 19, 2022 - Abstract #ATS2022ATS_2607;    
    The Philippines is among the countries with the most number of approved COVID-19 vaccines...The most common vaccine associated with breakthrough critical COVID-19 infection was Coronavac. This poses a challenge to public health policy on how best to implement a vaccination program that will mitigate risk for the development of critical covid infection post-vaccination.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Journal:  Severe Persistent Eczema in a Recipient of the Gam-COVID-Vac vaccine. (Pubmed Central) -  Feb 17, 2022   
    Moreover, a severe allergic reaction to a COVID-2019 vaccine may indicate the vaccine is ineffective in the recipient. Vaccination against COVID-19 may be accompanied by rare complications.Eczematous lesions can be a side effect of the Sputnik V vaccine.A severe allergic reaction to a COVID-19 vaccine may result in decreased vaccine effectiveness in the recipient.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Trial completion:  Sputnik-HD: Immune Response in Dialysis Patients Vaccinated Against COVID-19 (clinicaltrials.gov) -  Feb 17, 2022   
    P=N/A,  N=52, Completed, 
    Moreover, the population had appreciable attitude and positive perceptions towards Sputnik V vaccination. Active, not recruiting --> Completed
  • ||||||||||  Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford
    Review, Journal:  Review of COVID-19 viral vector-based vaccines and COVID-19 variants. (Pubmed Central) -  Feb 12, 2022   
    The technology has been used to make Ebola vaccines and now COVID-19 vaccines...Current adenovirus vector-based vaccines being administered against SARS-CoV-2 infection are JNJ-78435735 by Johnson and Johnson (Janssen) along with Beth Israel Deaconess Medical Center, AZD1222 by Oxford-AstraZeneca, Sputnik V and Sputnik Light by Gamaleya Research Institute of Epidemiology and Microbiology, and Convidecia vaccine by CanSino Biologics...Efficacy against COVID-19 variants has been found in all but the Convidecia vaccine so far. Heterologous prime-boost COVID-19 vaccination regimen may be the new face and more efficient immunization approach for enhanced immunity against COVID-19.
  • ||||||||||  Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Review, Journal, Adverse events:  A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges. (Pubmed Central) -  Feb 8, 2022   
    Apart from the common adverse effects such as fever, fatigue, headache, and pain in the injection site, Bell's palsy with BNT162b2, myocarditis and pericarditis with mRNA-1273, and thrombosis with ChAdOx1 nCoV-19 have been reported though seemed not alarming. Furthermore, global production and distribution of vaccines should be ensured in an equal and justifiable way that the immunity and protection against the virus would be optimum and persistent.
  • ||||||||||  BBIBP-CorV / Wuhan Institute of Virology, Sinopharm, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    SARS-CoV-2-specific T Cell Immunity after Vaccination with Sputnik V and BBIBP-CorV () -  Feb 4, 2022 - Abstract #AAAAI2022AAAAI_1970;    
    SARS-CoV-2-specific T cell responses developed in 26.6% and 31.6% of patients after Sputnik V and BBIBP-CorV vaccination, respectively. BBIBP-CorV vaccination also stimulated T cells specific to N and M antigens of SARS-CoV-2.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Journal:  Seroprevalence of SARS-Cov-2 Antibodies in Adults, Arkhangelsk, Russia. (Pubmed Central) -  Feb 1, 2022   
    In a survey of 1,080 residents of Arkhangelsk 40-75 years of age, 65% were seropositive for IgG. Fifteen percent of participants had been vaccinated; of those, 97% were seropositive.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Journal:  Evaluation of the Gam-COVID-Vac and vaccine-induced neutralizing response against SARS-CoV-2 lineage P.1 variant in an Argentinean cohort. (Pubmed Central) -  Jan 27, 2022   
    Herein, we show for the first time, evidence of infectious SARS-CoV-2 shedding from Sputnik-V fully vaccinated individuals, by the isolation of viable virus from the nasopharyngeal swab of one participant of our study, 139 days after receiving the second dose. Thereby, we provide evidence indicating that the vaccine might avoid severe forms of COVID-19 but does not prevent infection nor prevents transmission from a fully vaccinated individual.
  • ||||||||||  Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Clinical, Journal:  Efficacy of Covid-19 vaccines: several modes of expression should be presented in scientific publications. (Pubmed Central) -  Jan 18, 2022   
    Using main publications, absolute risks (AR), AR reduction (ARR), number needed to treat (NNT) were calculated for five COVID-19 vaccines (tozinameran Comirnaty®, Moderna, Vaxzevria®, Janssen, and Sputnik V vaccines)...The order of the different vaccines was not the same according to the chosen efficacy parameters. This is a further example of the need to express results of clinical trials, using not only RR, but also AR, ARR and NNT in order to clearly present the clinical interest of drugs.